Patents by Inventor Kristopher Raghavan

Kristopher Raghavan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Netrin G1 polypeptides
    Patent number: 12637502
    Abstract: The present disclosure provides polypeptides of netrin G1 (NetG1) and its cell surface receptor netrin G1 ligand (NGL1), and antibodies thereto, and methods of making such antibodies. The disclosure also provides uses of these NetG1 and NGL1 polypeptides, and antibodies thereto, in methods of treating cancers and diseases, including chronic fibrosis, inflammation, and inflammation-related diseases.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: May 26, 2026
    Assignee: INSTITUTE FOR CANCER RESEARCH
    Inventors: Edna Cukierman, Ralph Francescone, Debora Vendramini-Costa, Kristopher Raghavan, Janusz Franco-Barraza, Roland Dunbrack
  • Netrin G1 as a biomarker for enhancing tumor treatment efficacy
    Patent number: 12098193
    Abstract: The present disclosure provides methods of inducing desmoplastic stroma to express a normal phenotype by detecting increased levels of NetG1 or NGL1 in tumor or in desmoplastic stroma isolated from a human subject, and/or detecting NetG1 in circulating extracellular vesicles, and/or detecting increased pFAK in the stroma, and treating the human subject with a therapeutic regimen; and by detecting NetG1 in a microvesicle isolated from a human subject, and/or treating the human subject with a therapeutic regimen.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: September 24, 2024
    Assignee: Institute For Cancer Research
    Inventors: Edna Cukierman, Ralph Francescone, Janusz Franco-Barraza, Kristopher Raghavan
  • Netrin G1 And Netrin G1 Ligand Peptides And Antibodies And Uses Thereof
    Publication number: 20220289823
    Abstract: The present disclosure provides polypeptides of netrin G1 (NetG1) and its cell surface receptor netrin G1 ligand (NGL1), and antibodies thereto, and methods of making such antibodies. The disclosure also provides uses of these NetG1 and NGL1 polypeptides, and antibodies thereto, in methods of treating cancers and diseases, including chronic fibrosis, inflammation, and inflammation-related diseases.
    Type: Application
    Filed: April 24, 2020
    Publication date: September 15, 2022
    Inventors: Edna Cukierman, Ralph Francescone, Debora Vendramini-Costa, Kristopher Raghavan, Janusz Franco-Barraza, Roland Dunbrack
  • NETRIN G1 AS A BIOMARKER FOR ENHANCING TUMOR TREATMENT EFFICACY
    Publication number: 20210309729
    Abstract: The present disclosure provides methods of inducing desmoplastic stroma to express a normal phenotype by detecting increased levels of NetG1 or NGL1 in tumor or in desmoplastic stroma isolated from a human subject, and/or detecting NetG1 in circulating extracellular vesicles, and/or detecting increased pFAK in the stroma, and treating the human subject with a therapeutic regimen; and by detecting NetG1 in a microvesicle isolated from a human subject, and/or treating the human subject with a therapeutic regimen.
    Type: Application
    Filed: October 9, 2018
    Publication date: October 7, 2021
    Inventors: Edna Cukierman, Ralph Francescone, Janusz Franco-Barraza, Kristopher Raghavan